Managing CDIs is challenging due to their recurrent nature and the emergence of hypervirulent strains, such as the NAP1/027 strain. Treatment often involves antibiotics like metronidazole, vancomycin, or fidaxomicin, but recurrence rates remain high. Novel therapies, including fecal microbiota transplantation (FMT) and monoclonal antibodies, have shown promise in reducing recurrence rates.
